

# **Table of Contents**

## Table of Contents

---

<b>SECTION 1 MOLECULAR TARGETED THERAPIES IN ADVANCED RENAL CELL CARCINOMA.....</b>	<b>10</b>
<b>Introduction .....</b>	<b>11</b>
1. Epidemiology and clinical staging of renal cell carcinoma .....	12
2. Pathology and molecular characteristics of renal cell carcinoma.....	14
3. Oversight of systemic therapies for advanced renal cell carcinoma.....	20
4. Role of multitargeted tyrosine kinase inhibitors in renal cell carcinoma with focus on cabozantinib...	27
5. Non-clear cell renal carcinoma and brain metastases from renal cell carcinoma: Unmet need clinical entities .....	32
5.1 Advanced non-clear cell renal carcinoma.....	33
5.2 Brain metastases from renal cell carcinoma .....	36
<b>Objectives .....</b>	<b>39</b>
<b>Methods and results .....</b>	<b>41</b>
Project 1 - Cabozantinib in advanced non-clear cell renal carcinoma: a large multicenter retrospective cohort analysis.....	43
Project 2 - Activity and safety of cabozantinib in brain metastases from renal cell carcinoma: an international retrospective cohort study .....	54
<b>Discussion .....</b>	<b>68</b>
<b>Conclusions.....</b>	<b>78</b>
<b>SECTION 2 CYTOTOXIC AGENTS-BASED THERAPY IN NON-METASTATIC MUSCLE INVASIVE BLADDER CANCER.....</b>	<b>81</b>
<b>Introduction .....</b>	<b>82</b>
1. Epidemiology and clinical staging of bladder cancer .....	83
2. Histopathology and molecular characteristics of bladder cancer.....	87
3. Global management of non-metastatic muscle invasive bladder cancer with focus on systemic neoadjuvant approach .....	91
<b>Objectives .....</b>	<b>105</b>
<b>Methods and results .....</b>	<b>108</b>
Project 1 - Tumor infiltrating lymphocytes assessment in muscle invasive bladder cancer patients treated with cisplatin-based neoadjuvant chemotherapy and surgery.....	111
Project 2 – Avelumab, a PD-L1 inhibitor, as the basis of systemic neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) .....	120

Project 3 - Incidence, patterns and outcomes with adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy in muscle invasive urinary tract cancers. ....	135
<b>Discussion</b> .....	<b>145</b>
<b>Conclusions</b> .....	<b>160</b>
<b>SECTION 3 PERSPECTIVES REGARDING CYTOTOXIC AGENTS AND MOLECULAR-TARGETED THERAPY (INCLUDING IMMUNOTHERAPY) IN GENITOURINARY TUMORS</b> .....	<b>163</b>
<b>References</b> .....	<b>169</b>
References – Section 1 .....	170
References – Section 2 .....	183
<b>Appendixes</b> .....	<b>197</b>
Appendix I – Tables Section 1 .....	198
Appendix II – Figures Section 1.....	199
Appendix III – Tables Section 2.....	200
Appendix IV – Figures Section 2 .....	201
Appendix V – Abbreviations .....	202